IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting

Company will present “late-breaker” poster detailing updated clinical data from Phase 1 trial of INB-200

Company-sponsored Phase 2 trial of INB-400 to be showcased in Trials-in-Progress (TIPs) poster

NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that the Company will present two posters at the Society for Neuro-Oncology (SNO) 28^th Annual Meeting, taking place November 15-19, 2023, in Vancouver, British Columbia. The posters highlight the potential of IN8bio’s DeltEx Drug Resistant Immunotherapy (DRI), genetically modified and chemotherapy-resistant gamma-delta T cells to treat patients with newly diagnosed glioblastoma multiforme (GBM). The first poster is a TIPs poster detailing the study design for INB-400, the company-sponsored Phase 2 trial and the second will be a “late-breaker” poster providing updated clinical data from the Phase 1 INB-200 trial.

“Having recently initiated enrollment in our Phase 2 trial, we are excited to share details on the study’s design and look forward to providing updates as the trial progresses,” said Trishna Goswami, MD, Chief Medical Officer at IN8bio. “We are encouraged by the safety and preliminary efficacy signal we have seen in our Phase 1 trial treating GBM patients with autologous, genetically modified gamma-delta T cells. Using this approach, we hope to provide a new treatment for patients living with this cancer who currently have few therapeutic options and limited survival.”

Details for the SNO 2023 presentations:

Abstract #: CTIM-42 (Late-breakers)
Title: INB-200: Phase 1 Study of Gene Modified Autologous Gamma-delta (γδ) T Cells in Newly Diagnosed Glioblastoma Multiforme (GBM) Patients Receiving Maintenance Temozolomide (TMZ)

Presenter: Mina Lobbous, MD, MSPH, Cleveland Clinic, Case Western Reserve University
Session Name: Clinical Trials: Immunologic
Date and Time: Friday, November 17, 2023, 7:30 - 9:30 PM PT
Location: Exhibit Hall A/B

Abstract #: CTIM-35 (TIPs)
Title: INB-400 Phase 1b/2 Drug Resistant Immunotherapy with Activated, Gene Modified Allogeneic or Autologous γδ T Cells in Combination With Maintenance Temozolomide Recurrent or Newly Diagnosed Glioblastoma

Presenter: Burt Nabors, MD, Heersink School of Medicine, University of Alabama at Birmingham
Session Name: Clinical Trials: Immunologic
Date and Time: Friday, November 17, 2023, 7:30 - 9:30 PM PT
Location: Exhibit Hall A/B

Phase 2 Clinical Trial of INB-400 in GBM